English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve thein vitro activity of β-lactam antibiotics against bacteria of theMycobacterium abscessus complex (MABC). Here, we evaluated thein vitro activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC.

antimicrobial agents and chemotherapy

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the <i>In Vitro</i> Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates